Streetbeat News

Products Services

AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced that it will present a broad set of clinical and translational data from its programs at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The presentations will focus on rare blood disorders, including PK deficiency, thalassemia, sickle cell disease and anemia associated with lower-risk myelodysplastic syndromes (LR-MDS). The company's drug Mitapivat showed statistically significant hemoglobin response in Phase 2 of the RISE UP study in Sickle Cell Disease, supporting its advancement to Phase 3. Agios will also host a live and webcast investor event on Dec. 11, 2023.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:22 pm

CRVS

Corvus Pharmaceuticals will present new interim data from its Phase 1/1b T Cell Lymphoma trial of Soquelitinib at the 65th ASH Annual Meeting & Exposition.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:21 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced that seven abstracts have been accepted for presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition. This includes two presentations of updated clinical data from pivotal Phase 3 trials investigating exagamglogene autotemcel's potential as a one-time functional cure for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Five additional abstracts, including two on the improvements in patients' quality of life following treatment with exa-cel, have also been accepted.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:21 pm

VOR

Vor Bio (NASDAQ:VOR), a clinical-stage cell and genome engineering company, announced that preclinical and clinical data supporting its novel platform for treating acute myeloid leukemia (AML) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition. The data includes updates from the VBP101 clinical trial and the CD33CART Study. The company also released data from a single cell analysis studying molecular signatures from 28 AML patients and from a preclinical collaboration with Janssen. A trial-in-progress poster will be presented on the Company's VBP301 clinical trial.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:21 pm

INBX

Inhibrx, Inc. (NASDAQ:INBX) has announced preliminary efficacy and safety data from the Phase 1 trial of INBRX-109 in combination with Irinotecan and Temozolomide for the treatment of advanced or metastatic, unresectable Ewing sarcoma. The disease control rate was 76.9% among the 13 patients evaluated. The treatment was well tolerated with the most common adverse events being diarrhea, nausea, and fatigue.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:20 pm

STTK

Shattuck Labs, Inc. (NASDAQ:STTK) has announced the presentation of topline data from its Phase 1 A/B clinical trial of SL-172154, a bi-functional fusion protein for the treatment of patients with cancer and autoimmune disease. The data, which will be presented at the 65th ASH Annual Meeting, shows that SL-172154 demonstrates anti-leukemic activity and an acceptable safety and tolerability profile. The company is encouraged by the growing body of data that further validates the unique mechanism of action of SL-172154 and its therapeutic potential to address the unmet needs for patients with AML and HR-MDS.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:20 pm

INAB

In8bio is set to present new data from its Phase 1 trial of INB-100 at the 2023 ASH Annual Meeting. The data shows promising efficacy of INB-100 in patients with hematologic malignancies, with no dose-limiting toxicities and evidence of robust gamma-delta T cell expansion.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:19 pm

EEFT

Euronet (NASDAQ:EEFT) has announced a multi-year partnership with Banco Pichincha, Ecuador's largest private bank, for prepaid and debit card issuing and processing services. The partnership will involve the use of Euronet's Ren payments platform and will enable Pichincha to modernize its payments platform, comply with regulatory mandates, and introduce innovative products. The agreement also includes integration with Visa and Mastercard and will pave the way for the bank's digital transformation.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:19 pm

MARA

Marathon Digital Holdings (NASDAQ:MARA) has launched a Bitcoin mining pilot project in Utah, powered by landfill methane gas. The project is part of a broader initiative to capture methane from landfills, convert it into electricity, and use it to power Bitcoin miners. This could help reduce greenhouse gas emissions while utilizing a renewable and off-grid energy source. If successful, the company plans to expand its footprint in this area.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:18 pm

HYPR

An observational study has found that the Hyperfine Portable MR Brain Imaging System aids clinicians in the early detection of acute brain injury in ECMO patients. The results were presented at the 2023 Asia-Pacific Extracorporeal Life Support Organization (APELSO) meeting.

Portfolio Pulse from Benzinga Newsdesk

November 02, 2023 | 1:18 pm